Adoptive transfer of tumor-infiltrating lymphocytes in melanoma: a viable treatment option. Issue 1 (3rd October 2018)

• Record Type: Journal Article
• Authors: Rohaan, Maartje W.; van den Berg, Joost H.; Kvistborg, Pia; Haanen, John B. A. G.
• Is Part Of: Journal for immunotherapy of cancer. Volume 6:Issue 1(2018)
• Publication Date: 2018-10-03
• Subjects: Melanoma -- Adoptive cell therapy -- Tumor-infiltrating lymphocytes -- Immunotherapy -- Lymphodepletion -- Interleukin-2 -- Antigen recognition -- Combination therapy; Cancer -- Immunotherapy -- Periodicals; Cancer -- Immunological aspects -- Periodicals; Tumors -- Immunological aspects -- Periodicals; Immunotherapy -- Periodicals; 616.99406105
• DOI: 10.1186/s40425-018-0391-1
• Languages: English
• ISSNs: 2051-1426

Abstract

Abstract : The treatment of metastatic melanoma patients with autologous tumor-infiltrating lymphocytes (TIL) shows robust, reproducible, clinical responses in clinical trials executed in several specialized centers over the world. Even in the era of targeted therapy and immune checkpoint inhibition, TIL therapy can be an additional and clinically relevant treatment line. This review provides an overview of the clinical experiences with TIL therapy thus far, including lymphodepleting regimens, the use of interleukin-2 (IL-2) and the associated toxicity. Characteristics of the TIL products and the antigen recognition pattern will be discussed, as well as the current and upcoming production strategies, including the selective expansion of specific fractions from the cell product. In addition, the future potential of TIL therapy in melanoma and other tumor types will be covered.